Medicine's Rachel Weinerman clarifies FDA warning change for hormone therapy

Here's what RFK Jr., FDA got wrong about menopausal hormone therapy

Medpage Today: Rachel Weinerman, associate professor of reproductive biology and an OB/GYN and reproductive endocrinologist, clarified what the FDA's decision to remove the black box warning on menopausal hormone therapy products means to women. "What we've learned is that estrogen does provide cardiac protection ... but in a very specific way. It has to start within the very first few years of menopause in order to have a benefit, and if you wait too long before you start it, then it can actually be problematic and not provide that same benefit to women," said Weinerman.